{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:32:56Z","timestamp":1767677576475,"version":"3.48.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82070651"],"award-info":[{"award-number":["82070651"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82230019"],"award-info":[{"award-number":["82230019"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-02007-0","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T08:03:32Z","timestamp":1766995412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Finding appropriate timing for the combination of azathioprine and infliximab: propensity score matching and inverse probability of treatment weighting analysis"],"prefix":"10.1007","volume":"26","author":[{"given":"Keke","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6953-7816","authenticated-orcid":false,"given":"Yu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1193-4277","authenticated-orcid":false,"given":"Xiaowei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"issue":"4","key":"2007_CR1","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/00054725-200207000-00002","volume":"8","author":"J Cosnes","year":"2002","unstructured":"Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP. Long-term evolution of disease behavior of crohn\u2019s disease. Inflamm Bowel Dis. 2002;8(4):244\u201350.","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"2007_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","volume":"4","author":"GR Lichtenstein","year":"2006","unstructured":"Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. Serious infections and mortality in association with therapies for crohn\u2019s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4(5):621\u201330.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"2007_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/apt.14224","volume":"46","author":"M Eberhardson","year":"2017","unstructured":"Eberhardson M, S\u00f6derling JK, Neovius M, Cars T, Myrelid P, Ludvigsson JF, Askling J, Ekbom A, Ol\u00e9n O. Anti-TNF treatment in crohn\u2019s disease and risk of bowel resection-a population based cohort study. Aliment Pharmacol Ther. 2017;46(6):589\u201398.","journal-title":"Aliment Pharmacol Ther"},{"issue":"18","key":"2007_CR4","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, et al. Infliximab for the treatment of fistulas in patients with crohn\u2019s disease. N Engl J Med. 1999;340(18):1398\u2013405.","journal-title":"N Engl J Med"},{"issue":"4","key":"2007_CR5","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1053\/j.gastro.2005.01.048","volume":"128","author":"GR Lichtenstein","year":"2005","unstructured":"Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing crohn\u2019s disease. Gastroenterology. 2005;128(4):862\u20139.","journal-title":"Gastroenterology"},{"issue":"12","key":"2007_CR6","first-page":"656","volume":"15","author":"S Fine","year":"2019","unstructured":"Fine S, Papamichael K, Cheifetz AS. Etiology and management of lack or loss of response to Anti-Tumor necrosis factor therapy in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2019;15(12):656\u201365.","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"3","key":"2007_CR7","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/ibd\/izx065","volume":"24","author":"S Bots","year":"2018","unstructured":"Bots S, Gecse K, Barclay M, D\u2019Haens G. Combination immunosuppression in IBD. Inflamm Bowel Dis. 2018;24(3):539\u201345.","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"2007_CR8","first-page":"Cd000545","volume":"10","author":"N Chande","year":"2016","unstructured":"Chande N, Townsend CM, Parker CE, MacDonald JK. Azathioprine or 6-mercaptopurine for induction of remission in crohn\u2019s disease. Cochrane Database Syst Rev. 2016;10(10):Cd000545.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"2007_CR9","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1016\/j.cgh.2022.10.016","volume":"21","author":"AJ Yarur","year":"2023","unstructured":"Yarur AJ, McGovern D, Abreu MT, Cheifetz A, Papamichail K, Deepak P, Bruss A, Beniwal-Patel P, Dubinsky M, Targan SR, et al. Combination therapy with immunomodulators improves the pharmacokinetics of Infliximab but not Vedolizumab or ustekinumab. Clin Gastroenterol Hepatol. 2023;21(11):2908\u2013e29172910.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"2007_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1043-6618(02)00264-5","volume":"47","author":"ID Arnott","year":"2003","unstructured":"Arnott ID, Watts D, Satsangi J. Azathioprine and anti-TNF alpha therapies in crohn\u2019s disease: a review of pharmacology, clinical efficacy and safety. Pharmacol Res. 2003;47(1):1\u201310.","journal-title":"Pharmacol Res"},{"issue":"6","key":"2007_CR11","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.cgh.2019.10.035","volume":"18","author":"NH Nguyen","year":"2020","unstructured":"Nguyen NH, Singh S, Sandborn WJ. Positioning therapies in the management of crohn\u2019s disease. Clin Gastroenterol Hepatol. 2020;18(6):1268\u201379.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2007_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/00054725-200403000-00014","volume":"10","author":"GT Ho","year":"2004","unstructured":"Ho GT, Lees C, Satsangi J. Pharmacogenetics and inflammatory bowel disease: progress and prospects. Inflamm Bowel Dis. 2004;10(2):148\u201358.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"2007_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","volume":"13","author":"C Maaser","year":"2019","unstructured":"Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, Calabrese E, Baumgart DC, Bettenworth D, Borralho Nunes P, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019;13(2):144\u201364.","journal-title":"J Crohns Colitis"},{"issue":"15","key":"2007_CR14","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D\u2019Haens G, Diamond RH, Broussard DL, et al. Infliximab, azathioprine, or combination therapy for crohn\u2019s disease. N Engl J Med. 2010;362(15):1383\u201395.","journal-title":"N Engl J Med"},{"issue":"1","key":"2007_CR15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41598-021-04304-6","volume":"12","author":"TJ Jeong","year":"2022","unstructured":"Jeong TJ, Kim ES, Kwon Y, Kim S, Seo SW, Choe YH, Kim MJ. Discontinuation of azathioprine could be considered in pediatric patients with crohn\u2019s disease who have sustained clinical and deep remission. Sci Rep. 2022;12(1):507.","journal-title":"Sci Rep"},{"issue":"8","key":"2007_CR16","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1111\/jgh.14648","volume":"34","author":"CJ Ooi","year":"2019","unstructured":"Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, et al. Best practices on immunomodulators and biologic agents for ulcerative colitis and crohn\u2019s disease in Asia. J Gastroenterol Hepatol. 2019;34(8):1296\u2013315.","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl A","key":"2007_CR17","doi-asserted-by":"publisher","first-page":"a5","DOI":"10.1155\/2005\/269076","volume":"19","author":"MS Silverberg","year":"2005","unstructured":"Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world Congress of gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):a5\u201336.","journal-title":"Can J Gastroenterol"},{"issue":"10340","key":"2007_CR18","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","volume":"399","author":"M Ferrante","year":"2022","unstructured":"Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, et al. Risankizumab as maintenance therapy for moderately to severely active crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399(10340):2031\u201346.","journal-title":"Lancet"},{"issue":"1","key":"2007_CR19","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1186\/s12967-024-05317-1","volume":"22","author":"Y Li","year":"2024","unstructured":"Li Y, Sun R, Lai C, Liu K, Yang H, Peng Z, Xu D, Huang F, Tang K, Peng Y, et al. Hyperbaric oxygen therapy ameliorates intestinal and systematic inflammation by modulating dysbiosis of the gut microbiota in crohn\u2019s disease. J Transl Med. 2024;22(1):518.","journal-title":"J Transl Med"},{"issue":"1","key":"2007_CR20","doi-asserted-by":"publisher","first-page":"2236011","DOI":"10.1080\/07853890.2023.2236011","volume":"55","author":"Z Peng","year":"2023","unstructured":"Peng Z, Xu D, Li Y, Liu X, Li F, Peng Y. A novel role of prognostic nutritional index in predicting the effectiveness of Infliximab in crohn\u2019s disease. Ann Med. 2023;55(1):2236011.","journal-title":"Ann Med"},{"issue":"2","key":"2007_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2165\/00063030-200216020-00005","volume":"16","author":"GM Keating","year":"2002","unstructured":"Keating GM, Perry CM. Infliximab: an updated review of its use in crohn\u2019s disease and rheumatoid arthritis. BioDrugs. 2002;16(2):111\u201348.","journal-title":"BioDrugs"},{"issue":"10","key":"2007_CR22","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.1007\/s10620-024-08515-5","volume":"69","author":"JA Lowell","year":"2024","unstructured":"Lowell JA, Sharma G, Chua V, Ben-Horin S, Swaminath A, Sultan K. Reactive Immunomodulator addition to Infliximab monotherapy restores clinical response in inflammatory bowel disease: A Meta-Analysis. Dig Dis Sci. 2024;69(10):3920\u201331.","journal-title":"Dig Dis Sci"},{"key":"2007_CR23","doi-asserted-by":"crossref","unstructured":"Bots SJ, Parker CE, Brandse JF, Lowenberg M, Feagan BG, Sandborn WJ, Jairath V, D\u2019Haens G. Vande Casteele N: Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. BioDrugs 2021, 35(6):715\u2013733.","DOI":"10.1007\/s40259-021-00507-5"},{"issue":"9","key":"2007_CR24","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1136\/gut.2006.099978","volume":"56","author":"S Vermeire","year":"2007","unstructured":"Vermeire S, Noman M, Van Assche G, Baert F, D\u2019Haens G, Rutgeerts P. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to Infliximab in crohn\u2019s disease. Gut. 2007;56(9):1226\u201331.","journal-title":"Gut"},{"issue":"9","key":"2007_CR25","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1046\/j.1365-2036.2003.01778.x","volume":"18","author":"X Roblin","year":"2003","unstructured":"Roblin X, Serre-Debeauvais F, Phelip JM, Bessard G, Bonaz B. Drug interaction between Infliximab and azathioprine in patients with crohn\u2019s disease. Aliment Pharmacol Ther. 2003;18(9):917\u201325.","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"2007_CR26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, Van Assche G, Carbonez GDH, Rutgeerts A. Influence of immunogenicity on the long-term efficacy of Infliximab in crohn\u2019s disease. N Engl J Med. 2003;348(7):601\u20138.","journal-title":"N Engl J Med"},{"issue":"3","key":"2007_CR27","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1046\/j.1445-5994.2001.00039.x","volume":"31","author":"M Mortimore","year":"2001","unstructured":"Mortimore M, Gibson PR, Selby WS, Radford-Smith GL, Florin TH, Schering P. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of crohn\u2019s disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab user group. Intern Med J. 2001;31(3):146\u201350.","journal-title":"Intern Med J"},{"issue":"7","key":"2007_CR28","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","volume":"124","author":"JM Van den Brande","year":"2003","unstructured":"Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I, van Montfrans C, Hommes DW, Peppelenbosch MP, van Deventer SJ. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with crohn\u2019s disease. Gastroenterology. 2003;124(7):1774\u201385.","journal-title":"Gastroenterology"},{"issue":"8","key":"2007_CR29","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.cgh.2018.09.033","volume":"17","author":"JF Colombel","year":"2019","unstructured":"Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D\u2019Haens GR, Rutgeerts PJ, Reinisch W, Sandborn WJ, Hanauer SB. Combination therapy with Infliximab and azathioprine improves Infliximab Pharmacokinetic features and efficacy: A post hoc analysis. Clin Gastroenterol Hepatol. 2019;17(8):1525\u201332. e1521.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2007_CR30","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/MIB.0000000000001043","volume":"23","author":"JF Brandse","year":"2017","unstructured":"Brandse JF, Mould D, Smeekes O, Ashruf Y, Kuin S, Strik A, van den Brink GR, D\u2019Haens GR. A Real-life population Pharmacokinetic study reveals factors associated with clearance and immunogenicity of Infliximab in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(4):650\u201360.","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl 1","key":"2007_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000437077","volume":"33","author":"DR Mould","year":"2015","unstructured":"Mould DR. The pharmacokinetics of biologics: A primer. Dig Dis. 2015;33(Suppl 1):61\u20139.","journal-title":"Dig Dis"},{"issue":"17","key":"2007_CR32","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1161\/01.CIR.0000037521.71373.44","volume":"106","author":"D Hurlimann","year":"2002","unstructured":"Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, Bechir M, Spieker LE, Neidhart M, Michel BA, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation. 2002;106(17):2184\u20137.","journal-title":"Circulation"},{"key":"2007_CR33","doi-asserted-by":"crossref","unstructured":"Duan M, Lu M, Diao Y, Cao L, Wu Q, Liu Y, Gong J, Zhu W, Li Y. Azathioprine plus exclusive enteral nutrition versus azathioprine monotherapy for the prevention of postoperative recurrence in patients with Crohn\u2019s disease: an open-label, single-centre, randomised controlled trial. J Crohns Colitis 2024.","DOI":"10.1093\/ecco-jcc\/jjae015"},{"issue":"3","key":"2007_CR34","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.cgh.2014.07.027","volume":"13","author":"D Drobne","year":"2015","unstructured":"Drobne D, Bossuyt P, Breynaert C, Cattaert T, Vande Casteele N, Compernolle G, J\u00fcrgens M, Ferrante M, Ballet V, Wollants WJ, et al. Withdrawal of immunomodulators after co-treatment does not reduce trough level of Infliximab in patients with crohn\u2019s disease. Clin Gastroenterol Hepatol. 2015;13(3):514\u2013e521514.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"2007_CR35","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1007\/s10620-020-06600-z","volume":"66","author":"K Zeze","year":"2021","unstructured":"Zeze K, Hirano A, Torisu T, Esaki M, Moriyama T, Umeno J, Kawasaki K, Fujioka S, Fuyuno Y, Matsuno Y, et al. Adding thiopurine after loss of response to Infliximab versus early combination in treating crohn\u2019s disease: A retrospective study. Dig Dis Sci. 2021;66(9):3124\u201331.","journal-title":"Dig Dis Sci"},{"key":"2007_CR36","doi-asserted-by":"crossref","unstructured":"Abbas A, Koleva YN, Khan N. Su1131 Incidence Rate of Lymphoma by the Cumulative Duration of Exposure to Thiopurines: A Nationwide Retrospective Cohort From the Veterans\u2019 Affairs Healthcare System. Gastroenterology 2013, 144(5, Supplement 1):S-406-S-407.","DOI":"10.1016\/S0016-5085(13)61498-5"},{"issue":"1","key":"2007_CR37","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s00384-023-04378-w","volume":"38","author":"B Han","year":"2023","unstructured":"Han B, Tang D, Lv X, Li S, Fan J, Xu X, Zhang J, Xu S, Ye W, Huang Z, et al. Comparative efficacy and safety of combination therapy with Infliximab for crohn\u2019s disease: a systematic review and network meta-analysis. Int J Colorectal Dis. 2023;38(1):82.","journal-title":"Int J Colorectal Dis"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-02007-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-02007-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-02007-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:29:47Z","timestamp":1767677387000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-02007-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2007"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-02007-0","relation":{},"ISSN":["1591-9528"],"issn-type":[{"type":"electronic","value":"1591-9528"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}